A family office that has been actively investing for several years, is supported by well-established Chinese partners and supports companies in venturing globally. To date, the firm has made over 20 investments, mostly in the medical device space. The firm focuses on making seed investments up to $500K, with $200K being the average check size. The firm is open to global opportunities.

The firm invests across all sectors of life sciences, including therapeutics, medical devices, diagnostics, and digital health, with most of its investments having been in medtech companies. The firm is technology agnostic and is open to all kinds of high potential opportunities.

The firm seeks to work with management teams with strong academic credentials and significant experience in successfully launching early-stage ventures. The firm prefers to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a trans-Atlantic venture investment firm focused on building innovative Life Sciences businesses in the UK, Europe and the USA. The firm has a highly experienced team that focuses on turning break-through science into approved medicines or medical products.

The firm starts and invests in early and mid-stage companies with a first-in-class or best-in-class approach. The investments are focused in new drug discovery – small molecules, biologics and new modalities – med tech, enabling technologies and vaccines.

The firm’s team are well connected team and experienced, and the team supports each investment. The firm works in close alignment with management teams, and partners with them to realize their vision and achieve financial returns by bringing innovation to patients.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment and management company headquartered in South Korea has ~$500M assets under management, and has a strong product/partnership portfolio in oncology, cardiovascular, CNS, anti-infection, among others. The firm has invested in an early-stage cell therapy company in South Korea, and is actively seeking early-stage (Seed to Series A) investment opportunities, and will also consider investments into VC funds that have aligned interest areas. The firm seeks to invest between $1-2M with capacity for up to $5M per company for initial investment, with potential for follow-on investments for promising companies that achieve milestones. The firm is actively seeking for global opportunities.

The firm is most interested in companies developing novel drugs in oncology, immunology, and rare disease indications and/or novel platform technologies for drug development. The firm will consider different types of modalities but is most interested in small molecules and biologics. In terms of stage of development, the firm is most interested in pre-clinical or early clinical stage companies.

The firm has a preference for working with experienced management teams – significant experience in drug development or senior management in global pharma or large biotech is considered a huge plus. The firm highly prefers companies that have a strong IP portfolio.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office investment vehicle with offices in USA and Western Europe is looking to provide equity capital to USA-based therapeutic companies. The firm usually invests in Series A or B rounds, and will consider to participate in a seed round of financing. The firm’s typical deal size is variable, generally going as high as $5M for an initial investment.

The firm is currently looking for companies developing Therapeutics. The firm is opportunistic in terms of sub-sector and indication though they do have a preference for companies with platform technologies. The firm is willing to invest in companies with a lead asset in preclinical through Phase II of clinical trials. The firm’s portfolio includes oncology, the microbiome, pain, neurological and rare diseases biotech companies.

The firm looks to invest in companies with experienced management teams. The firm is capable to act as either a lead or a co-lead investor and generally seeks board or board observer rights. As a pro-active investor, The firm will assist in the growth of a company, recruit new talents, develop preclinical, clinical and IP strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm that is based in Western USA with its parent company based in China, currently has invested in over 39 companies across a wide variety of sectors including biotech, IoT, AI, etc. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. With their first fund, the firm preferred to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K.

Now, the firm is currently raising a second fund with a target size of $200M, through which the firm hopes to invest more capital in later rounds (i.e. Series A to B) and provide follow on investments to portfolio companies. Through the second fund, the firm is also seeking to expand their interests in diagnostics, digital health, and novel therapeutics. The e firm is in the process of launching an accelerator program to support the growth of early-stage companies in the sectors mentioned above and provide these companies with valuable resources, especially for global market entry and tapping into their network of China-based investors and partners. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, digital health, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA is focused on early and growth-stage biotech and medical device companies. The group’s initial investments typically are in the $3M-$5M range and are usually in the form of straight equity, but may use convertible notes in select situations. The firm look to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs, such as Boston or San Francisco.

The firm is most interested in the biotech/therapeutics space and will consider medtech companies on a secondary basis. The firm does not invest in diagnostic or digital health companies. The firm is mostly opportunistic in terms of technology type and indication area, however the group prioritizes companies with products addressing unmet medical need and unique mechanisms of action. For early-stage companies, the firm targets companies who have at least had a pre-IND meeting with the FDA and invest in companies ranging from pre-clinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office investment vehicle representing the interests of USA East Coast based family offices, is looking to invest in ground-breaking life science and medical device technologies. While the firm is very flexible in terms of investment size, they are generally looking to invest a minimum of $0.5 million per round. The firm is open to Investing in companies located throughout North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis and is especially interested in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell-based therapeutics. The firm is less interested in small molecules and generally will not consider biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease-modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency. For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.